HEMO — Hemogenyx Pharmaceuticals Cashflow Statement
0.000.00%
Last trade - 00:00Annual cashflow statement for Hemogenyx Pharmaceuticals, fiscal year end - December 31st, GBP millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -5.11 | -3.99 | -6.7 | -5.63 | -9.77 |
| Depreciation | |||||
| Non-Cash Items | 2.25 | 0.648 | 0.779 | 0.243 | 4.98 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 0.101 | 0.243 | -0.834 | 0.603 | 0.749 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Payable / Accrued Expenses | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -2.63 | -2.9 | -6.11 | -4.14 | -3.45 |
| Capital Expenditures | -0.818 | -0.429 | -0.117 | -0.013 | -0.004 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | -0.121 | 0.009 | 0.085 | 0.012 | -0.003 |
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -0.939 | -0.42 | -0.032 | -0.002 | -0.007 |
| Financing Cash Flow Items | 0 | — | — | — | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 8.78 | -0.11 | 4.45 | 3.08 | 4.89 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 5.03 | -4.31 | -1.29 | -1.09 | 1.43 |